CP and neoplasm: As shown in Figure 1c, the volume of the vehicle‐treated (VEH) tumours increased by 119 ± 51% at Day 4, while the volume of the combination‐treated cohorts increased only by 29 ± 29% and 48 ± 32% respectively for ORL/CP D0 (p < 0.01 compared with VEH) and ORL/CP D2 (p < 0.05 compared with VEH).